» Articles » PMID: 33175511

Druggable Hot Spots in the Schistosomiasis Cathepsin B1 Target Identified by Functional and Binding Mode Analysis of Potent Vinyl Sulfone Inhibitors

Abstract

Schistosomiasis, a parasitic disease caused by blood flukes of the genus , is a global health problem with over 200 million people infected. Treatment relies on just one drug, and new chemotherapies are needed. cathepsin B1 (SmCB1) is a critical peptidase for the digestion of host blood proteins and a validated drug target. We screened a library of peptidomimetic vinyl sulfones against SmCB1 and identified the most potent SmCB1 inhibitors reported to date that are active in the subnanomolar range with second order rate constants () of ∼2 × 10 M s. High resolution crystal structures of the two best inhibitors in complex with SmCB1 were determined. Quantum chemical calculations of their respective binding modes identified critical hot spot interactions in the S1' and S2 subsites. The most potent inhibitor targets the S1' subsite with an -hydroxysulfonic amide moiety and displays favorable functional properties, including bioactivity against the pathogen, selectivity for SmCB1 over human cathepsin B, and reasonable metabolic stability. Our results provide structural insights for the rational design of next-generation SmCB1 inhibitors as potential drugs to treat schistosomiasis.

Citing Articles

Differential Excretory/Secretory Proteome of the Adult Female and Male Stages of the Human Blood Fluke, .

Kenney E, Mann V, Ittiprasert W, Rosa B, Mitreva M, Bracken B Front Parasitol. 2025; 1():950744.

PMID: 39816473 PMC: 11732030. DOI: 10.3389/fpara.2022.950744.


Computational Workflow to Design Novel Vaccine Candidates and Small-Molecule Therapeutics for Schistosomiasis.

Balogun E, Joseph G, Olabode S, Dayaso N, Danazumi A, Bashford-Rogers R Pathogens. 2024; 13(10).

PMID: 39452722 PMC: 11509903. DOI: 10.3390/pathogens13100850.


Pharmacophore Virtual Screening Identifies Riboflavin as an Inhibitor of the Schistosome Cathepsin B1 Protease with Antiparasitic Activity.

Cogo R, Pavani T, Mengarda A, Cajas R, Teixeira T, Fukui-Silva L ACS Omega. 2024; 9(23):25356-25369.

PMID: 38882094 PMC: 11170711. DOI: 10.1021/acsomega.4c03376.


Nature-Inspired Gallinamides Are Potent Antischistosomal Agents: Inhibition of the Cathepsin B1 Protease Target and Binding Mode Analysis.

Spiwokova P, Horn M, Fanfrlik J, Jilkova A, Fajtova P, Leontovyc A ACS Infect Dis. 2024; 10(6):1935-1948.

PMID: 38757505 PMC: 11184554. DOI: 10.1021/acsinfecdis.3c00589.


Chemo-informatics applications in the design of novel 7-keto-sempervirol derivatives as SmCB1 inhibitors with potential for treatment of Schistosomiasis.

Anyubaga S, Shallangwa G, Uzairu A, Abechi S Heliyon. 2024; 10(1):e23115.

PMID: 38173516 PMC: 10761359. DOI: 10.1016/j.heliyon.2023.e23115.


References
1.
Betts M, STERNBERG M . An analysis of conformational changes on protein-protein association: implications for predictive docking. Protein Eng. 1999; 12(4):271-83. DOI: 10.1093/protein/12.4.271. View

2.
Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B . Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2011; 1824(1):68-88. PMC: 7105208. DOI: 10.1016/j.bbapap.2011.10.002. View

3.
Engel J, Doyle P, Hsieh I, McKerrow J . Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med. 1998; 188(4):725-34. PMC: 2213346. DOI: 10.1084/jem.188.4.725. View

4.
Fajtova P, Stefanic S, Hradilek M, Dvorak J, Vondrasek J, Jilkova A . Prolyl Oligopeptidase from the Blood Fluke Schistosoma mansoni: From Functional Analysis to Anti-schistosomal Inhibitors. PLoS Negl Trop Dis. 2015; 9(6):e0003827. PMC: 4454677. DOI: 10.1371/journal.pntd.0003827. View

5.
Jilkova A, Horn M, Mares M . Structural and Functional Characterization of Schistosoma mansoni Cathepsin B1. Methods Mol Biol. 2020; 2151:145-158. DOI: 10.1007/978-1-0716-0635-3_12. View